New Mexico Hematology and Breast Cancer Conference

Albuquerque, NM US
February 2, 2024 to February 3, 2024

The New Mexico Hematology and Breast Cancer Conference is a CME-accredited, in-person hematology oncology conference featuring leading hematology and breast cancer experts. Expert faculty will place key abstract findings from the 65th ASH Annual Meeting (ASH2023) and the San Antonio Breast Cancer Symposium (SABCS2023) into clinical context and discuss how the results may change the current standards of care for patients with benign and malignant hematologic disorders and breast cancer. This conference is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care.

This conference allows attendees an opportunity to discuss current research and advances in the field of hematologic disorders and breast cancer with colleagues and key opinion leaders. The goals of this conference are to review and critically assess the results of practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients. 

Target Audience

  • Hematologists, Oncologists
  • Surgeons
  • Radiation Oncologists
  • Physician Assistants/Nurse Practitioners
  • Pharmacists
  • Nurses

Organizing Committee 

Course Director:

Binay Shah, MD, MHA Binaytara Foundation

Co-Chairs:

Bernard Tawfik, MD - University of New Mexico Comprehensive Cancer Center

Ethan Binder, MD - Presbyterian Medical Group

Organizing Committee:

Charles Foucar, MD - University of New Mexico Comprehensive Cancer Center

Anna Maria Voltura, MD - X-Ray Associates of New Mexico

Shashank Cingam, MD - University of New Mexico Comprehensive Cancer Center

Ala Ebaid, MD - University of New Mexico Comprehensive Cancer Center

Venue Information 

Rooms have been set aside on February 2-4, 2024, at the rate of $179.00 plus taxes per night (Single Occupancy).

(Booking Link):   ASH/SABCS

(Call In Code): ASH/SABCS

Individuals may contact our reservations team to book via phone at (505) 843-6300.

Please note the Reservation and Rooming List Cut-Off Date will be: January 3, 2024. 

Learning Objectives

  1. Review data presented at the ASH2023 and SABCS2023 & discuss their applications in clinical settings.    
  2. Choose new therapeutic options for treating benign and malignant hematologic disorders & breast cancer, understanding appropriate indications and contraindications to these therapeutic approaches.
  3. Discuss the study design and primary endpoints of recently reported and ongoing trials that have influenced the changes in the standards of care in hematology and breast cancer.
  4. Integrate evolving diagnostic, prognostic, and therapeutic approaches to managing hematologic disorders and breast cancer patients.
  5. Individualize management of patients based on emerging data from clinical trials and evolving expert guidelines.

Global Oncology Project

To learn more about our ongoing project building a 200-bed cancer hospital in Nepal:

Course summary
Available credit: 
  • 8.25 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.25 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.25 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.25 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.25 Contact Hours.
Course opens: 
11/02/2023
Course expires: 
05/02/2024
Event starts: 
02/02/2024 - 4:00pm PST
Event ends: 
02/03/2024 - 4:35pm PST
Cost:
$150.00

DAY 1 - February 2, 2024

All times are listed in Mountain Time (MT)

04:00 – 04:45 PM: Registration and networking


04:45 – 05:00 PM: Opening remarks


05:00 – 06:30 PM: Session 1 – Classical Hematology: Case-based discussion

Moderator: Mitchell Binder, MD

Case 1 - Bleeding disorder - Colin Murphy, MD

Case 2 - Clotting disorder - Apoorva Cheeti, MD

Case 3 - ITP - Sardar Zakariya Imam, MD

Case 4 - TTP - Jay Raval, MD

Case 5 - Anemia - Clifton ‘Kip’ Layman, DO

Case 6 - Bone marrow failure - Dulcinea Quintana, MD


06:30 – 07:15 PM: Networking and reception


DAY 2 - February 3, 2024

08:00 – 09:30 AM: Session 2

Moderator: Charles Foucar, MD

08:00 - 08:25 AM: MDS/Acute Leukemia - Bachar Samra, MD

08:25 - 08:50 AM: Myeloproliferative neoplasms and CML - Yubao Wang, MD, PhD

08:50 - 09:15 AM: Cellular therapy in hematologic malignancies – recent updates - Matthew Fero, MD

09:15 - 09:30 AM: Q & A


09:30 – 10:00 AM:  Break and exhibits


10:00 – 11:45 AM: Session 3

Moderator: Andrea Teague, MD

10:00 - 10:25 AM: Lymphoma - Krishna Moturi, MD

10:25 - 10:50 AM: Chronic lymphocytic leukemia - Ethan Binder, MD

10:50 - 11:15 AM: Multiple myeloma - Shashank Cingam, MD

11:15 - 11:45 AM: Q & A


11:45 AM – 12:45 PM: Lunch and exhibits


12:45 – 02:25 PM: Session 4

Moderator: Bernard Tawfik, MD

12:45 - 01:10 PM: Pre-malignancy/high risk breast cancer - Mahmoud Abdelsamia, MD

01:10 - 01:35 PM: Hormone receptor positive breast cancer - Fei Gu, MD, PhD

01:35 - 02:00 PM: HER2 positive breast cancer - Katherine Sanchez, MD

02:00 - 02:25 PM: Triple negative and HER2 low breast cancer - Jacklyn Nemunaitis, MD


02:25 – 02:40 PM: Break and exhibits


02:40 – 04:30 PM: Session 5

Moderator: Anna Voltura, MD

02:40 - 03:05 PM: Radiotherapy – best breast practice - Amit Garg, MD

03:05 - 03:30 PM: Updates in surgical approach – best breast practice - Anna Voltura, MD

03:30 - 03:45 PM: Q & A

03:45 - 04:30 PM: Case-based discussion

Case 1 - DCIS - Linda Smith, MD, FACS

Case 2 - Inflammatory breast cancer - Jennifer Bishop, MD

Case 3 - Early stage breast cancer - Sangeetha Prabhakaran, MD


04:30 – 04:35 PM: Adjourn

HOTEL ALBUQUERQUE AT OLD TOWN
800 Rio Grande Blvd. NW
Albuquerque, NM 87104
United States

Rooms have been set aside on February 2-4, 2024, at the rate of $179.00 plus taxes per night (Single Occupancy).

(Booking Link):   ASH/SABCS

(Call In Code): ASH/SABCS

Individuals may contact our reservations team to book via phone at (505) 843-6300.

Please note the Reservation and Rooming List Cut-Off Date will be: January 3, 2024. 

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Course Director(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.
Conference Chair(s)

Ethan Binder, MD

has no relevant financial relationships to disclose at this time.

Bernard Tawfik, MD

has no relevant financial relationships to disclose at this time.
Speaker/Topic Presenter(s)

Mahmoud Abdelsamia, MD

has no relevant financial relationships to disclose at this time.

Ethan Binder, MD

has no relevant financial relationships to disclose at this time.

Matthew Fero, MD

has no relevant financial relationships to disclose at this time.

Amit Garg, MD

has no relevant financial relationships to disclose at this time.

Fei Gu, MD PhD

has no relevant financial relationships to disclose at this time.

Krishna Rekha Moturi

has no relevant financial relationships to disclose at this time.

Jackie Nemunaitis, MD

has no relevant financial relationships to disclose at this time.

Bachar Samra, MD

has no relevant financial relationships to disclose at this time.

Katherine Sanchez, MD

has no relevant financial relationships to disclose at this time.

Anna Voltura

has no relevant financial relationships to disclose at this time.

Yubao Wang

has no relevant financial relationships to disclose at this time.
Case Presenter(s)

Jennifer Bishop, MD, FACS

has no relevant financial relationships to disclose at this time.

Apoorva Cheeti

has no relevant financial relationships to disclose at this time.

Sardar Imam, MBBS

has a financial relationship (Other) with Cardinal Health;.
has a financial relationship (Other) with Exelixis;.
has a financial relationship (Other) with Janssen Pharmaceuticals;.
has a financial relationship (Other) with Pharmacyclics;.
has a financial relationship (Other) with AbbVie;.
has a financial relationship (Other) with Boston Biomedical;.
has a financial relationship (Other) with QED Therapeutics;.
has a financial relationship (Other) with Pfizer;.
has a financial relationship (Other) with Novartis;.
has a financial relationship (Other) with Astra Zenica;.
has a financial relationship (Other) with SeaGen;.

Clifton 'Kip' Layman, DO

has a financial relationship (Independent contractor) with Astra Zeneca;.
has a financial relationship (Independent contractor) with Bristol Myers Squibb;.
has a financial relationship (Independent contractor) with Sanofi;.
has a financial relationship (Independent contractor) with Regeneron;.

Colin Murphy, MD

has no relevant financial relationships to disclose at this time.

Sangeetha Prabhakaran, MD FACS

has a financial relationship (Other) with Biotheranostics;.

Dulcinea Quintana

has no relevant financial relationships to disclose at this time.

Jay Raval, MD

has a financial relationship (Professional Services) with Sanofi SA;.

Linda Smith, Md

has no relevant financial relationships to disclose at this time.
Moderator(s)

Mitchell Binder, MD

has no relevant financial relationships to disclose at this time.

Andrea Teague, Board Certified in Hematology and Oncology

has a financial relationship (Gift) with Curio Science;.

Anna Voltura

has no relevant financial relationships to disclose at this time.
Planning committee(s)

Shashank Cingam

has no relevant financial relationships to disclose at this time.

Ala Ebaid

has a financial relationship (Other) with Sobi;.

Charles Foucar, MD

has no relevant financial relationships to disclose at this time.

Anna Voltura

has no relevant financial relationships to disclose at this time.

Available Credit

  • 8.25 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.25 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.25 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.25 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.25 Contact Hours.

If you are interested in exhibiting at this meeting, please complete this form: https://education.binayfoundation.org/New-Mexico-ASH-SABCS24-Sponsorship-Form

 

Price

Cost:
$150.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

If your company has purchased an exhibit or sponsorship, please register at the link below to receive the discounted registration fees:

Link to register as an additional rep of a sponsoring company: https://education.binayfoundation.org/industry_registraiton_nocme 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.